3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
30
Nivolumab
15
Paclitaxel
13
Cyclophosphamide
12
Carboplatin
12
sacituzumab govitecan
8
Cisplatin
8
Capecitabine
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
fludarabine
5
durvalumab
5
avelumab
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Biopsy
5
camrelizumab
4
Specimen Handling
4
Interleukin-2
4
Injections
4
Immune Checkpoint Inhibitors
4
Docetaxel
4
toripalimab
3
talazoparib
3
Leucovorin
3
Everolimus
3
Clinical Trials, Phase II as Topic
3
Bevacizumab
3
yeast-CEA vaccine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Triple Negative Breast Neoplasms
×
utomilumab
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts